Tumors with loss of NF1, both benign tumors such as pNF, and high-grade malignancies including MPNST, are characterized by hyperactivation of RAS/RAF/MEK/ERK signaling. This evidence concerns the gene MAP2K7 and malignant peripheral nerve sheath tumor.